
Redwire Chief Scientist Dr. Kenneth Savin Named to TIME's 2025 TIME100 Health List of the 100 Most Influential People in Global Health
Dr. Savin was selected for his deep expertise in the pharmaceutical industry and his pioneering work accelerating cutting-edge space biotech research capabilities, which leverage microgravity to improve human health on Earth. At Redwire, Dr. Savin has overseen trailblazing investigations onboard the International Space Station (ISS) in partnership with NASA and the ISS National Laboratory. Redwire successfully bioprinted the first human knee meniscus and first live human cardiac tissue using its BioFabrication Facility on the ISS. These breakthroughs address challenges faced by millions of people worldwide through the application of organ transplantation and tissue therapy and advance the next generation of pharmaceutical therapies.
Dr. Savin has coordinated groundbreaking protein crystallization investigations onboard the ISS with pharmaceutical companies like Eli Lilly and Company (Lilly) and Bristol Myers Squibb using Redwire's in-space pharmaceutical lab, PIL-BOX, for improved drug development. These investigations have focused on various applications to address the world's most prevalent conditions, including antiviral, antifungal, and antiseizure applications, heart disease, and bone loss.
'I am deeply honored to be recognized as one of the TIME100's most influential figures in health for 2025,' said Dr. Savin. 'Through microgravity research and development, we are seeing extraordinary scientific achievements that are accelerating game changing biomedical breakthroughs not possible on Earth and with enormous potential for the future of human health. I am honored and proud to be part of the Redwire team and excited to see what we are able to accomplish next."
Before joining Redwire, Dr. Savin had a successful 20-year career in the pharmaceutical industry working at Lilly, where he led various research and development teams, along with five investigations onboard the ISS. Following his time at Lilly, Dr. Savin was the Senior Director of In-Space Production Applications at the Center for the Advancement of Science In Space (manager of the ISS National Lab), where he worked with NASA to develop the In Space Production and Applications program to develop products in space that will benefit life on the Earth.
The full TIME100 Health list can be found here.
About Redwire
Redwire Corporation (NYSE:RDW) is a global space infrastructure and innovation company enabling civil, commercial, and national security programs. Redwire's proven and reliable capabilities include avionics, sensors, power solutions, critical structures, mechanisms, radio frequency systems, platforms, missions, and microgravity payloads. Redwire combines decades of flight heritage and proven experience with an agile and innovative culture. Redwire's approximately 750 employees working from 17 facilities located throughout the United States and Europe are committed to building a bold future in space for humanity, pushing the envelope of discovery and science while creating a better world on Earth. For more information, please visit redwirespace.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
UnitedHealth Group's (UNH) Healthcare Dominance: A Key Player in the Dogs of the Dow
UnitedHealth Group Incorporated (NYSE:UNH) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A senior healthcare professional giving advice to a patient in a clinic. The stock has dropped over 44% so far this year after reporting weaker-than-expected earnings in the first quarter. The company first reduced its full-year outlook and later chose to withdraw it entirely. Even with the underwhelming Q1 performance, UnitedHealth Group Incorporated (NYSE:UNH) still posted a 9.8% year-over-year increase in revenue, reaching $109.6 billion. It earned a profit of around $6.3 billion during the quarter and maintained a solid financial position, holding close to $34.3 billion in cash and cash equivalents, along with a debt level that remains manageable. The company has added 780,000 new members so far this year. Meanwhile, Optum Health still expects to provide value-based care to an additional 650,000 patients in 2025. In addition, UnitedHealth Group Incorporated (NYSE:UNH) generated $5.5 billion in operating cash flow during the quarter and returned $5 billion to investors through dividends and share repurchases. The company has been rewarding shareholders with growing dividends since 2011 and currently offers a quarterly dividend of $2.21 per share. The stock supports a dividend yield of 3.15%, as of July 26. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Why Yield-Focused Investors Favor Chevron (CVX) in the Dogs of the Dow Portfolio
Chevron Corporation (NYSE:CVX) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. An aerial view of an oil rig at sea, the sun glinting off its structure. It is currently facing some company-specific challenges, including a complicated merger and operations in politically unstable regions. However, these issues are unlikely to affect its long-term prospects. Income-focused investors can generally feel confident investing in Chevron. Chevron Corporation (NYSE:CVX)'s integrated business model, covering everything from exploration and production to refining and chemicals, offers operational flexibility and acts as a natural hedge against fluctuations in energy prices, enhancing its resilience through market cycles. Unlike many competitors who chase volume growth, Chevron takes a disciplined approach, investing only in its highest-return projects, avoiding overexpansion during booms, and making strategic, value-adding acquisitions. This strategy, along with a strong balance sheet, establishes Chevron Corporation (NYSE:CVX) as a leading operator with the financial strength to endure downturns and seize growth opportunities. The company has been growing its dividends for 38 consecutive years and currently offers a quarterly dividend of $1.71 per share. As of July 26, the stock has a dividend yield of 4.42%. While we acknowledge the potential of CVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Yahoo
19 minutes ago
- Yahoo
Coca-Cola's (KO) Timeless Appeal Among the Dogs of the Dow
The Coca-Cola Company (NYSE:KO) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A row of factory workers assembling bottles of sparkling soft drinks on a conveyor belt. The stock has surged by nearly 12% since the start of 2025, outperforming the broader market. Investors have shown strong interest in the stock this year for a number of reasons. It's often seen as a safe choice during market downturns because of its stability, making it a popular pick when uncertainty rises. More recently, confidence in The Coca-Cola Company (NYSE:KO) has been boosted by its strong position against potential tariff impacts. In addition, the company reported strong earnings in the second quarter of 2025. Its revenue came in at $12.6 billion, up 1% from the same period last year. The revenue beat analysts' estimates by $42 million. Operating income rose by 63%, while on a comparable currency-neutral basis (non-GAAP), it saw a 15% increase. The Coca-Cola Company (NYSE:KO) also remains investors' favorite because the company has been growing its payouts for 63 consecutive years. The company pays a quarterly dividend of $0.51 per share and has a dividend yield of 2.95%, as of July 26. While we acknowledge the potential of KO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data